Company intelligence / Profile preview
ADvantage Therapeutics
Miami, Florida, USAadvantagetherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company's lead compound AD04™ is in confirmatory Phase 2b clinical trials in Europe and the UK for early Alzheimer's Disease patients. In previous trials, AD04™ demonstrated statistically significant slower decline in cognitive and quality of life clinical measures compared to other treatment groups, as well as slower decline in hippocampal volume as a biomarker.
- Therapeutic areas
- OtherNeurology
- Modalities
- ImmunomodulatorKlotho protein therapies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Longevitytech.fund
Beyond the preview
Go deeper on ADvantage Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADvantage Therapeutics.